MedTrace Logo

Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction

NCT03198585 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2020-02-05

No results posted yet for this study

Summary

To assess the effect of Empagliflozin on cardiac biomarkers, cardiac function at rest and during stress, cardiac hemodynamics, renal function, metabolism, daily activity level and health-related quality of life in stable, symptomatic heart failure patients with reduced left ventricular ejection fraction.

The primary hypothesis is that 3 months' treatment with Empagliflozin 10 mg a day will reduce the plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP).

Conditions

  • Heart Failure With Reduced Ejection Fraction

Interventions

DRUG

Empagliflozin 10 MG

Capsule, once a day for 90 days

OTHER

Placebo

Capsule, once a day for 90 days

Sponsors & Collaborators

  • Morten Schou

    lead OTHER

Principal Investigators

  • Morten Schou, MD · Herlev and Gentofte University Hospital

  • Jacob E Moller, MD · Odense University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-29
Primary Completion
2019-12-20
Completion
2020-01-17

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03198585 on ClinicalTrials.gov